NASDAQ:NRC National Research Q2 2023 Earnings Report $10.69 +0.06 (+0.56%) As of 04/24/2025 04:00 PM Eastern Earnings History National Research EPS ResultsActual EPS$0.29Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANational Research Revenue ResultsActual Revenue$36.16 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANational Research Announcement DetailsQuarterQ2 2023Date8/1/2023TimeN/AConference Call DateWednesday, August 2, 2023Conference Call Time11:00AM ETUpcoming EarningsNational Research's Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 11:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by National Research Q2 2023 Earnings Call TranscriptProvided by QuartrAugust 2, 2023 ShareLink copied to clipboard.There are 3 speakers on the call. Operator00:00:00Hello, and welcome to today's National Research Corporation Second Quarter 2023 Earnings Call. My name is Bailey, and I'll be your moderator for today. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. I'd now like to pass the conference over to Kevin Curas, Chief Financial Officer. Please go ahead. Speaker 100:00:28Thank you, Bailey, and welcome, everyone, to National Research Corporation's 2023 Second Quarter Earnings Call. My name is Kevin Karas, the company's CFO. And joining me on the call today is Linda Stacy, our Vice President of Finance. Before we continue, I'd like to ask Linda to review conditions related to any forward looking statements that may be made As part of today's call. Linda? Speaker 200:00:55Thank you, Kevin. This conference call includes forward looking statements related to the company that involve risks and uncertainties That could cause actual results or outcomes to differ materially from those currently anticipated. These forward looking statements are made pursuant to the Safe Harbor provisions of the Private For further information about the facts that could affect the company's future results, Please see the company's filings with the Securities and Exchange Commission. With that, I'll turn it back to you, Kevin. Speaker 100:01:24Thanks, Linda, and again, welcome, everyone. Over the past several quarters, we have significantly expanded our sales force and marketing spend, focused on supporting the rollout of our human understanding Well, it's early days. The material expansion of sales and marketing resources has been very effective in building A stronger sales pipeline and in the Q2 of 2023, we gained momentum in converting opportunities, Which resulted in a 53% increase in new sales compared to the Q2 of 2022. Today, 1 third of our Human Understanding Program clients are from new logos, with 2 thirds representing adoption of the program from current partner organizations. Contract value growth for human understanding program adoption by existing clients It's been 12%, which is in line with results from the successful rollout of our real time solution several years ago. Speaker 100:02:27Let me turn the call back over to Linda to review our financial performance and then open the call for questions. Speaker 200:02:33Thank you, Kevin. Revenue for the Q2 of 2023 decreased compared to the Q2 of 2022 by 3%, partially attributed to the closure of our Canadian operations and discontinuation of other non core solutions. We ended the quarter with $146,600,000 in TRCV, including a 1% increase in TRCV for our core solutions. Our TRC metric represents the total revenue projected under all renewable contracts for their respective next annual renewal periods assuming the up sells, down Price increases or cancellations measured as of the most recent quarter end. Operating income decreased by 19 for the Q2 of 2023 compared to the Q2 of 2022, primarily due to the decline in revenue And growth and marketing expenses of $906,000 to expand brand recognition and support sales development. Speaker 200:03:29We have been focusing on the alignment of our cost structure with business requirements, and the results were positive this quarter. Although we increased spending for sales and marketing expansion, We were able to reduce consolidated operating expenses, resulting in a 2.4% gross margin and a 1 point 2% operating income margin improvement in the 2nd quarter as compared to the Q1 of 2023. We are implementing other cost alignment changes that will enable continued quarterly margin improvement in future quarters. The effective tax rate in the Q2 of 2023 was 23% compared to 25% in 2022, primarily due to increased tax benefits from the exercise of share based compensation awards. The company's Board of Directors maintain its capital allocation priorities of funding innovation and growth investments, including merger and acquisition activity, As well as internal projects, shareholder dividends and share repurchases during 2023. Speaker 200:04:27In the Q2 of 20 The company funded $4,200,000 for innovation and growth, dollars 3,000,000 for dividend payments and $1,800,000 for share repurchases. That concludes my comments for this morning. I'll now turn the call back to you, Kevin. Speaker 100:04:44This completes our prepared remarks. So Bailey, I will ask you to open the call to any questions. Operator00:04:50Thank There are currently no registered questions. So I'd like to pass the call back to the management team for any closing remarks. Speaker 100:05:43Thank you. Just would like to close by thanking everyone for your time today, And we look forward to sharing our results again next quarter.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallNational Research Q2 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) National Research Earnings HeadlinesNational Research Appoints New Financial OfficerApril 22 at 5:14 PM | tipranks.comNational Research Stock Short Interest Report | NASDAQ:NRC | BenzingaApril 21, 2025 | benzinga.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 25, 2025 | Paradigm Press (Ad)National Research Stock Price, Quotes and Forecasts | NASDAQ:NRC | BenzingaApril 20, 2025 | benzinga.comShould You Be Impressed By National Research Corporation's (NASDAQ:NRC) ROE?April 18, 2025 | finance.yahoo.comA New Era of Trust: NRC Health’s 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare ExperienceApril 10, 2025 | finance.yahoo.comSee More National Research Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like National Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on National Research and other key companies, straight to your email. Email Address About National ResearchNational Research (NASDAQ:NRC) provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.View National Research ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step InWhy It May Be Time to Buy CrowdStrike Stock Heading Into EarningsCan IBM’s Q1 Earnings Spark a Breakout for the Stock? Upcoming Earnings AbbVie (4/25/2025)AON (4/25/2025)Colgate-Palmolive (4/25/2025)HCA Healthcare (4/25/2025)NatWest Group (4/25/2025)Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 3 speakers on the call. Operator00:00:00Hello, and welcome to today's National Research Corporation Second Quarter 2023 Earnings Call. My name is Bailey, and I'll be your moderator for today. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. I'd now like to pass the conference over to Kevin Curas, Chief Financial Officer. Please go ahead. Speaker 100:00:28Thank you, Bailey, and welcome, everyone, to National Research Corporation's 2023 Second Quarter Earnings Call. My name is Kevin Karas, the company's CFO. And joining me on the call today is Linda Stacy, our Vice President of Finance. Before we continue, I'd like to ask Linda to review conditions related to any forward looking statements that may be made As part of today's call. Linda? Speaker 200:00:55Thank you, Kevin. This conference call includes forward looking statements related to the company that involve risks and uncertainties That could cause actual results or outcomes to differ materially from those currently anticipated. These forward looking statements are made pursuant to the Safe Harbor provisions of the Private For further information about the facts that could affect the company's future results, Please see the company's filings with the Securities and Exchange Commission. With that, I'll turn it back to you, Kevin. Speaker 100:01:24Thanks, Linda, and again, welcome, everyone. Over the past several quarters, we have significantly expanded our sales force and marketing spend, focused on supporting the rollout of our human understanding Well, it's early days. The material expansion of sales and marketing resources has been very effective in building A stronger sales pipeline and in the Q2 of 2023, we gained momentum in converting opportunities, Which resulted in a 53% increase in new sales compared to the Q2 of 2022. Today, 1 third of our Human Understanding Program clients are from new logos, with 2 thirds representing adoption of the program from current partner organizations. Contract value growth for human understanding program adoption by existing clients It's been 12%, which is in line with results from the successful rollout of our real time solution several years ago. Speaker 100:02:27Let me turn the call back over to Linda to review our financial performance and then open the call for questions. Speaker 200:02:33Thank you, Kevin. Revenue for the Q2 of 2023 decreased compared to the Q2 of 2022 by 3%, partially attributed to the closure of our Canadian operations and discontinuation of other non core solutions. We ended the quarter with $146,600,000 in TRCV, including a 1% increase in TRCV for our core solutions. Our TRC metric represents the total revenue projected under all renewable contracts for their respective next annual renewal periods assuming the up sells, down Price increases or cancellations measured as of the most recent quarter end. Operating income decreased by 19 for the Q2 of 2023 compared to the Q2 of 2022, primarily due to the decline in revenue And growth and marketing expenses of $906,000 to expand brand recognition and support sales development. Speaker 200:03:29We have been focusing on the alignment of our cost structure with business requirements, and the results were positive this quarter. Although we increased spending for sales and marketing expansion, We were able to reduce consolidated operating expenses, resulting in a 2.4% gross margin and a 1 point 2% operating income margin improvement in the 2nd quarter as compared to the Q1 of 2023. We are implementing other cost alignment changes that will enable continued quarterly margin improvement in future quarters. The effective tax rate in the Q2 of 2023 was 23% compared to 25% in 2022, primarily due to increased tax benefits from the exercise of share based compensation awards. The company's Board of Directors maintain its capital allocation priorities of funding innovation and growth investments, including merger and acquisition activity, As well as internal projects, shareholder dividends and share repurchases during 2023. Speaker 200:04:27In the Q2 of 20 The company funded $4,200,000 for innovation and growth, dollars 3,000,000 for dividend payments and $1,800,000 for share repurchases. That concludes my comments for this morning. I'll now turn the call back to you, Kevin. Speaker 100:04:44This completes our prepared remarks. So Bailey, I will ask you to open the call to any questions. Operator00:04:50Thank There are currently no registered questions. So I'd like to pass the call back to the management team for any closing remarks. Speaker 100:05:43Thank you. Just would like to close by thanking everyone for your time today, And we look forward to sharing our results again next quarter.Read morePowered by